Work

Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps3109

Authors: Ignacio Melero Bermejo, Elizabeth M. Jaffee, Diwakar Davar, Josephine Cardarelli, Daphne Williams, Penny Phillips, Michael Carleton, Ming Zhou, Olivier De Henau, Manish Monga, Charles G. Drake

Institutions: Clinica Universidad de Navarra, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, UPMC Hillman Cancer Center, Bristol-Myers Squibb (United States), Columbia University Irving Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2892330807

Cites:

Cited by: 6

Related to: 10